

Asian Gastrointestinal Oncology Research Group (AGIORG) Educational Webinar
Independent Medical Education Sponsorship by Pierre Fabre
 APAC Expert Consensus Guidelines in *BRAF*mutant mCRC
 14th November 6.00pm – 6.50pm (Date may change subject to publication)

Abstract:

The newly founded academic organisation AGIORG will host an educational webinar on September 26th, supported via an independent medical education sponsorship by Pierre Fabre. The webinar will focus on the APAC Expert Consensus Guidelines for BRAFV600E mutant metastatic colorectal cancer (mCRC) (publication pending). Objectives include increasing awareness about the latest guidelines, identifying treatment challenges in Asia, and encouraging oncologists to enhance treatment pathways. Key speakers, including Prof Iain Tan, Prof Brigitte Ma, and A/Prof Hsu, will review current evidence, discuss real-world cases, and highlight practical management strategies. The session aims to provide valuable insights for medical oncologists in Asia.

Objectives:

- Describe the latest APAC expert consensus guideline, including the key recommendations and treatment guideline
- Identify and discuss key factors contributing to challenges in treatment considerations for BRAFV600E mutant mCRC patients in Asia
- Encourage Medical Oncologists to consider strategies in enhancing treatment pathway and management for BRAFV600E mutant mCRC patients based on the Expert Consensus Statements recently published

Time	Topic	Facilitator/Speaker
5 minutes	Introduction & Objectives <ul style="list-style-type: none"> ○ Introduce AGIORG organisation ○ Review objectives of the webinar 	Prof Iain Tan Singapore
10 minutes	Review of current evidence in the treatment of <i>BRAF</i> mutant mCRC in context of Asia <ul style="list-style-type: none"> ○ Current evidence and international guidelines for <i>BRAF</i>mutant mCRC management ○ Review of challenges <i>BRAF</i>mutant mCRC patients face in Asia (testing, access, outcomes) 	Prof Brigitte Ma Hong Kong
10 minutes	Bringing the “evidence to patients” – a case study <ul style="list-style-type: none"> ○ Presentation of real-world <i>BRAF</i>mutant mCRC case ○ Discussing evidence and APAC guidelines on management of real-world <i>BRAF</i>mutant mCRC case ○ Discussion and highlighting challenges patients may face, and how to manage these 	A/Prof Hsu Taiwan Interactive discussion with Prof Iain Tan & Prof Brigitte Ma
20 minutes	Q&A with expert panel <ul style="list-style-type: none"> ○ Opportunity to receive and answer questions from audience members 	All
5 minutes	Close <ul style="list-style-type: none"> ○ Key take-aways to medical oncologists in Asia on practical management of <i>BRAF</i>mutant mCRC 	Prof Iain Tan Singapore

Scientific Faculty Biography



A/Prof Iain Tan – Singapore

A/Prof Iain Tan is Senior Consultant Medical Oncologist and the Director of Research for the Division of Medical Oncology. He is a colorectal medical oncologist and NMRC clinician scientist-senior investigator awardee. His research spans translational research, clinical trials, and Public Health. He is a principal Investigator of the Laboratory of Applied Cancer Genomics at the Genome Institute of Singapore, A-Star, and faculty at CSCB, Duke-NUS. He is the clinical chair of Singapore's colorectal cancer large collaborative grant program, Colo-SCRIPT. A/Prof Iain collaborates widely with clinicians, scientists, and public health practitioners. He leads several data science efforts in Singhealth and is the platform lead for Tissue bank/Data & Population Health and Impact for Singapore Translational Cancer Consortium. A firm believer in team science, together with his partners, he has published widely in top journals (e.g., Nature, Nature Genetics, JAMA, Cancer Discovery) in CRC, public health, and data science.



Prof Brigette Ma – Hong Kong

Prof Brigette Ma is currently Professor and Honorary Consultant at the Department of Clinical Oncology, Chinese University of Hong Kong (CUHK), Medical Director of the Phase I Clinical Trial Centre (Oncology) and Chair of the NTEC-CUHK ethics committee for phase 1 studies. She received her undergraduate degree with Honours at Monash University, Australia, and was awarded Fellow of the Royal Australasian College of Physicians, Fellow of Hong Kong College of Physicians, and Doctor of Medicine (CUHK). She underwent training in Medical Oncology at the Peter MacCallum Cancer Institute, Melbourne, and was Research Fellow at the Princess Margaret Hospital, Toronto, Canada. She has published over 200 peer-reviewed papers. Notably, she had been a Faculty member of the European Society of Medical Oncology (ESMO) in Gastrointestinal Cancer, and was a member of the Consensus Working Group for the management of metastatic colorectal cancer; executive member of the National Cancer Institute (Bethesda, USA) Head and Neck Cancer Steering Committee - Clinical Trials Planning Group on Nasopharyngeal Cancer, Co-chair of Widely Metastatic Group; and mentor and committee member of the Women in Cancer Research of the American Association of Cancer Research. Her other current roles included: member of the Joint Scientific Committee for Phase 1 Clinical Trials, Centre of Health Protection, Hong Kong Hospital Authority; Track Chair/ member of the Scientific Committee American Association of Cancer Research, ESMO congresses. She is co-Scientific chair of ESMO (Asia) conference in Singapore and co-chairs for some ESMO advanced course/ workshops concerning early drug development. She is Associate Editor of Oral Oncology and is member of the Editorial Board for ESMO Open (GI) and Clinical Colorectal Cancer amongst other journals.



A/Prof Hung-Chih Hsu – Taiwan

Dr. Hung-Chih Hsu is an associate professor and attending physician of Division of Hematology/Oncology, Chang Gung Memorial Hospital. A/Prof. Hsu graduated from Medical Department of Taipei Medical University, and later obtained his Ph.D. degree from Graduate Institute of Clinical Medicine, Chang Gung University. He was a research fellow in Department of Basic Science, UC Davis Medical Cancer Center. His clinical focus is colorectal cancer, and was involved in several key studies, including BREAKWATER, KEYNOTE-177, DESTINY-CRC02, etc.